In the realm of ovarian cancer treatment, preventing venous thromboembolism (VTE) is a crucial step in improving patient outcomes post-surgery. SHR-2004, a promising FXI-blocking antibody developed by Hengrui Pharmaceuticals, has demonstrated significant potential in VTE prevention for ovarian cancer patients. Prisys Biotech (浦灵生物), a leader in preclinical research services, played a pivotal role in bringing SHR-2004 from concept to clinical trials. This article delves into the development of SHR-2004, its clinical trial results, and how Prisys Biotech's expertise contributed to its success.
Understanding the VTE Challenge in Ovarian Cancer
VTE is a common and potentially deadly complication in ovarian cancer patients, particularly after surgery. Studies show that the risk of VTE in ovarian cancer patients post-operation can range from 10% to 30%. In advanced or recurrent stages, this risk is even higher, making effective prevention essential to patient survival. The need for a safer and more effective anticoagulant therapy has never been more pressing.
SHR-2004 Clinical Trial: A Step Towards Safer Treatment
SHR-2004, originally developed as BJTJ-1837, has shown promising results in clinical trials. In the SHR-2004-202 Phase II trial, conducted with ovarian cancer patients, SHR-2004 demonstrated a significantly lower rate of VTE (12.6%) compared to the control group (20.2%). Importantly, SHR-2004 had no major bleeding events, offering a safer alternative to current anticoagulants. These results marked a significant advancement in VTE prevention, providing a safer, more effective treatment option for cancer patients.
Prisys Biotech's Crucial Role in Development
As a leading Contract Research Organization (CRO), Prisys Biotech's contribution was instrumental in advancing SHR-2004. With their expertise in non-human primate (NHP) models, A-V Shunt Model. Prisys Biotech conducted essential preclinical research to assess SHR-2004's pharmacodynamics, pharmacokinetics, and safety profile. Their cutting-edge imaging technology and AI-driven systems enabled precise data collection, ensuring that SHR-2004 was thoroughly evaluated before moving into clinical trials.
was incubated with tested antibody (100 μg/mL) or negative control for 5 minute at 37 ◦C. FXIa substrate S-2366 was added to measure FXIa
activity.
Prisys Biotech's innovative platforms, such as their real-time MRI technology for drug delivery and AI-powered behavioral analysis systems, provided a detailed understanding of SHR-2004's effectiveness in preventing thrombus formation without significant bleeding risks. This extensive preclinical work was critical to the success of the clinical trials.
were probed with BJTJ-1837, positive control (14E11-hFc, the variable domain of the murine precursor of AB023 fused to human IgG4/kappa
constant domains), or negative control (NOV1090, a MAA868 precursor) respectively, and further probed with anti–hFc-HRP secondary
antibody
The Future of VTE Prevention and SHR-2004
SHR-2004 has the potential to be a game-changer in preventing VTE, particularly for cancer patients, who are at higher risk due to surgery and chemotherapy. With its superior safety profile, SHR-2004 offers a novel, targeted approach to anticoagulation, with fewer risks of bleeding compared to traditional therapies. As the clinical trials continue to evolve, SHR-2004 may soon become a standard in the management of VTE in oncology patients.
Prisys Biotech: Your Partner in Drug Development
Prisys Biotech continues to offer invaluable preclinical research services, from drug efficacy testing to safety assessments, using non-human primate models and advanced technologies. By partnering with Prisys Biotech, pharmaceutical companies can ensure their products are ready for clinical trials with data that meet the highest standards of safety and effectiveness.
If you're looking to accelerate your drug development process, reach out to Prisys Biotech and discover how our services can help bring your treatments to life.
SHR-2004 is poised to revolutionize VTE prevention in ovarian cancer patients. Thanks to the groundbreaking preclinical research conducted by Prisys Biotech, SHR-2004 has reached clinical success, offering hope for better patient outcomes with fewer complications. As a leader in preclinical research, Prisys Biotech is proud to be part of this significant medical advancement.
Ma T, Weng Z, Cao B, Dong Y,. The first-in-human study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the factor XI monoclonal antibody SHR-2004 in healthy subjects. Expert Opin Investig Drugs. 2024 Oct;33(10):1075-1082. doi: 10.1080/13543784.2024.2391837. Epub 2024 Aug 22. PMID: 39166425.
He X, Zhang J, Du Y, Liu X. BJTJ-1837, a novel FXI activation-blocking antibody. Res Pract Thromb Haemost. 2023 Feb 7;7(2):100067. doi: 10.1016/j.rpth.2023.100067. PMID: 36936858; PMCID: PMC10017418.
